HONG KONG – Shenzhen-listed Harbin Gloria Pharmaceuticals Co. Ltd. plans to acquire a major stake in insulin maker Hefei Tianmai Biotechnology Development Co. Ltd. (HTBT) for ¥4 billion (US$600 million). Gloria is after HTBT's lead product, an oral insulin being co-developed with Israeli company Oramed Pharmaceuticals Inc.